Rossari Biotech FY25 Results: Revenue up 13.6%

Why Rossari Biotech’s annual numbers matter

Rossari Biotech Limited’s latest annual financial snapshot points to steady top-line growth, but also shows that profitability did not rise at the same pace. FY25 revenue increased, while operating and net profit margins moved lower versus FY24. The company’s cash flow from operations improved sharply in FY25, and the data also highlights changes across depreciation, finance costs, and other income. Alongside annual performance, recent quarterly disclosures and dividend details offer investors more context on near-term execution.

FY25 income statement: revenue grew, margins eased

For FY25, Rossari Biotech reported total revenues of ₹2,095.2 crore (₹20,952 million), compared with ₹1,844.7 crore (₹18,447 million) in FY24. Net sales rose to ₹2,080.3 crore in FY25 from ₹1,830.6 crore in FY24, reflecting 13.6% year-on-year growth. Other income increased to ₹14.9 crore in FY25 from ₹14.1 crore in FY24, up 5.5%.

Profitability expanded in absolute terms but not on a margin basis. Gross profit rose to ₹255.2 crore in FY25 from ₹243.3 crore in FY24, a 4.9% increase. Gross profit margin (presented in the data as a margin metric) stood at 12.3% in FY25 versus 13.3% in FY24. Profit after tax increased to ₹136.4 crore (₹1,364 million) from ₹130.7 crore (₹1,307 million), a 4.4% rise.

Costs and below-the-line movements in FY25

Expense line items in the FY25 summary show mixed trends. Depreciation increased to ₹67.1 crore in FY25 from ₹60.4 crore in FY24, up 11.1%. Interest costs declined to ₹17.8 crore from ₹19.4 crore, down 8.1%. Profit before tax increased to ₹185.2 crore from ₹177.6 crore, a 4.3% rise.

Tax expense rose to ₹48.8 crore in FY25 from ₹46.9 crore in FY24, up 4.0%. The effective tax rate was shown at 26.4% in both FY24 and FY25 in the income statement table. With margins narrowing, the net profit margin declined to 6.6% in FY25 from 7.1% in FY24.

Cash flow: operating cash flow improved sharply

The cash flow data indicates a notable change in operating cash generation. Cash flow from operations (CFO) for FY25 is reported at ₹137.4 crore (₹1,374 million), compared with ₹43.3 crore (₹433 million) in FY24. In the accompanying analysis summary, CFO during FY25 is also described as ₹100 crore (₹1 billion), improving 217.8% year-on-year.

Investing cash flow (CFI) in FY25 is reported at ₹-183.7 crore (₹-1,837 million), versus ₹-103.2 crore (₹-1,032 million) in FY24. Financial cash flow (CFF) increased to ₹64.9 crore (₹649 million) in FY25 from ₹16.2 crore (₹162 million) in FY24. Net cash flows for FY25 were stated at ₹19.0 crore (₹190 million) versus ₹-44.0 crore (₹-440 million) in FY24.

Revenue mix: Specialty Chemicals and India led contribution

A separate revenue breakdown in the data indicates Rossari Biotech’s revenue for the last year amounted to ₹2,080.0 crore (20.80 billion INR). Of this, ₹2,068.0 crore (20.68 billion INR) came from Specialty Chemicals - Products, compared with ₹1,822.0 crore (18.22 billion INR) in the year earlier.

Geographically, India contributed ₹1,523.0 crore (15.23 billion INR) in the last year, compared with ₹1,383.0 crore (13.83 billion INR) in the year before. These figures help explain where the company’s growth has been concentrated, based on the dataset provided.

Key FY24 vs FY25 financials (₹ crore)

Dividend and corporate actions in the data

The dataset lists an upcoming dividend of ₹0.50 dated July 30, 2025, and a paid dividend of ₹0.50 dated September 22, 2024. Another dividend table shows a cash dividend of ₹0.50 with declaration date April 29, 2024 and record date August 16, 2024. It also lists prior years, including a cash dividend of ₹0.50 with record date May 24, 2023.

From an investor perspective, these disclosures point to small per-share cash distributions, with the dividend yield in one market snapshot shown at 0.08%.

Quarterly disclosure: Q2 FY26 update and Q4 FY25 snapshot

A Regulation 30 (LODR) press release dated October 16 reported Q2 FY26 revenue of ₹586.1 crore (up 18%), EBITDA of ₹71.9 crore, and PAT of ₹36.9 crore. The same disclosure noted new capacities commissioned and an investment of up to approximately USD 8 million in Saudi Arabia.

Separately, a quarterly snapshot shows revenue of ₹581.50 crore and net profit of ₹34.44 crore for Q4 2024-2025, with a net profit margin of 5.92%. The data also states that Q4 revenue rose 22.86% year-on-year and net profit rose 0.91% year-on-year, while net profit margin fell 17.87% versus the same period last year.

Valuation and balance sheet pointers mentioned

The valuation snapshot in the dataset shows trailing twelve-month EPS at ₹24.6, improving from ₹23.7 last year, with a P/E of 27.9 times at a stated price of ₹682.3. Another market snapshot lists market cap at ₹3,602 crore, current price at ₹650, and 52-week high/low of ₹885/₹568.

On leverage, the data notes debt-to-equity at 0.1 in FY25 versus 0.0 in FY24. Profitability ratios shown include ROCE at 15.8% and ROE at 12.2%, and another table reference shows ROE at 12.47.

What to track next

FY25 data shows Rossari Biotech growing revenue faster than profits, with margin compression visible in both operating and net profit margins. At the same time, FY25 operating cash flow improved materially versus FY24, which can be a key monitor for earnings quality. Investors tracking near-term performance will likely watch follow-through from the Q2 FY26 update, including the impact of new capacities and the stated Saudi investment plan. Dividend timelines in the dataset also indicate an upcoming ₹0.50 payout dated July 30, 2025.